Description
“ Graft vs . Host Disease- Competitive Landscape , Technology and Pipeline Analysis , 2016 ”, report provides comprehensive insights about pipeline drugs across this indication . A key objective of the report is to establish the understanding for all the pipeline drugs that fall under the category of Graft Versus Host Disease . Graft-versus-host disease ( GVHD ) is a common complication of allogeneic hematopoietic stem cell transplantation ( HSCT ) that occurs when the donated ( graft ) cells are rejected and attack the host ' s cells as foreign .
Request a sample of this report @ http :// www . orbisresearch . com / contacts / request-sample / 209352 .
The complexity of immune-mediated disease occurs due to the interaction between the adaptive immunity of donor and recipient . It can progress from mild to severe forms as either acute GVHD ( aGVHD ) or chronic GVHD ( cGVHD ). Both aGVHD and cGVHD commonly affect organs such as the skin , gastrointestinal ( GI ) tract , liver , oral mucosa , and eyes . It is the worldwide cause of mortality and morbidity . Several factors are responsible for Graft versus Host Disease such as blood transfusion , bone marrow transplant , stem cell transplant .
Leading Companies Profiles Analyzed in Report :
• Bellicum Pharmaceuticals
• Kymab Limited
• Targazyme
• Multistem
• ImmuneTarget Inc .
• Athersys
• AstraZeneca plc .
• Fate Therapeutics , Inc .
• Therakos Inc .
• Mallinckrodt Pharmaceuticals
• Athersys
• AstraZeneca plc .
Purchase a copy of this report @ http :// www . orbisresearch . com / contact / purchase / 209352
Report Highlights :
• The new report , provides a Graft Versus Host Disease Landscape across the globe
• The report provides drug profiles which includes product description , MOA , licensors & collaborators , development partner and chemical information
• Comparative analysis at various stages covering Filed , Phase III , Phase II , Phase I , Preclinical and Discovery stages www . orbisresearch . com ; + 1 ( 214 ) 884-6817 ; + 9120-64101019